Episodit
-
Do you know how to differentiate between growth hormone deficiency (or GHD) and primary IGF-I deficiency (or growth hormone resistance) and the key challenges in the diagnosis and management of patients with short stature conditions?
For children presenting with short stature, an early and correct diagnosis is essential to allow children to achieve their full growth potential with appropriate treatment. Listen as expert pediatric endocrinologists delve into these rare growth disorders.
Join Prof. Philippe Backeljauw (Professor at Cincinnati Children's Hospital Medical Center and the University of Cincinnati, Cincinnati, USA) and Prof. Dr. Joachim Woelfle (Chairman of Pediatrics, Director of the Department of Pediatric and Adolescent Medicine at the Friedrich Alexander University Erlangen, Germany) as they engage in a conversation regarding key challenges in the diagnosis and management of patients with short stature conditions.
The experts discuss the incidence of patients with GHD and severe primary IGF-I deficiency and how to differentiate these conditions based on clinical presentation as well as biochemical and genetic testing. The importance of taking a good medical history and physical examination is discussed, as well as various caveats related to biochemical and genetic testing. Regional differences in the diagnosis of these patients are covered as well as key challenges in the diagnosis and management. Finally, the experts discuss the different treatment options as well as the importance of ensuring caregivers are well-informed regarding the efficacy and safety of the respective treatments.
This is the first video podcast episode in a two-part series on patients with severe short stature.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/pe-connect/programmes/rare-growth-disorders-podcast/
Or go to the video on YouTube:
https://youtu.be/OfI3lZgjew0
Download the transcript:
https://cor2ed.com/pe-connect/programmes/rare-growth-disorders-podcast/This Podcast is endorsed by the Magic Foundation. Find out more on their website: https://www.magicfoundation.org/The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen. This podcast is developed by COR2ED.com
-
Do you know how to differentiate between growth hormone deficiency (or GHD) and primary IGF-I deficiency (or growth hormone resistance) and the key challenges in the diagnosis and management of patients with short stature conditions?
For children presenting with short stature, an early and correct diagnosis is essential to allow children to achieve their full growth potential with appropriate treatment. Listen as expert pediatric endocrinologists delve into these rare growth disorders.
Join Prof. Philippe Backeljauw (Professor at Cincinnati Children's Hospital Medical Center and the University of Cincinnati, Cincinnati, USA) and Prof. Dr. Joachim Woelfle (Chairman of Pediatrics, Director of the Department of Pediatric and Adolescent Medicine at the Friedrich Alexander University Erlangen, Germany) as they engage in a conversation regarding key challenges in the diagnosis and management of patients with short stature conditions.
The experts discuss the incidence of patients with GHD and severe primary IGF-I deficiency and how to differentiate these conditions based on clinical presentation as well as biochemical and genetic testing. The importance of taking a good medical history and physical examination is discussed, as well as various caveats related to biochemical and genetic testing. Regional differences in the diagnosis of these patients are covered as well as key challenges in the diagnosis and management. Finally, the experts discuss the different treatment options as well as the importance of ensuring caregivers are well-informed regarding the efficacy and safety of the respective treatments.
This is the first video podcast episode in a two-part series on patients with severe short stature.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/pe-connect/programmes/rare-growth-disorders-podcast/
Or go to the video on YouTube:
https://youtu.be/OfI3lZgjew0
Download the transcript:
https://cor2ed.com/pe-connect/programmes/rare-growth-disorders-podcast/This Podcast is endorsed by the Magic Foundation. Find out more on their website: https://www.magicfoundation.org/The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen. This podcast is developed by COR2ED.com
-
Puuttuva jakso?
-
Gene therapy and gene-modified cell therapies have a great potential for rare diseases to either help patients to cure their disease or improve their lives. Did you know that gene therapy will probably become a major treatment option for many rare diseases in the near future? Listen as expert hematologists delve into this topic and take hemophilia as a practical example.
Join Prof. Cédric Hermans (Head of the Division of Haematology, the Hemostasis and Thrombosis Unit and the Hemophilia Center of the Saint-Luc University Hospital in Brussels, Belgium) and Prof. Miguel Escobar (Professor of Medicine and Pediatrics, University of Texas Health Science Center at Houston-McGovern Medical School and University of Texas M.D. Anderson Cancer Center Medical Director, Gulf States Hemophilia & Thrombophilia Center Houston, USA) as they engage in a conversation about the potential of gene and gene-modified cell therapies in rare diseases, and how early gene therapies have been implemented as a treatment approach for rare diseases, such as leber congenital amaurosis, spinal muscular atrophy, beta-thalassemia, adrenoleukodystrophy, and hemophilia.
The experts explore hemophilia as an example of how gene therapy has become a reality within rare diseases. They discuss why we need gene therapy for rare disease, what gene therapy and gene modified cell therapy is, and how this has become a reality in hemophilia, and look to the future of gene therapy for rare diseases. Finally they reflect on the importance of a multidisciplinary approach.
- Access information on the programme, the clinical takeaways, the flashcard and the transcript here https://cor2ed.com/hemostasis-connect/programmes/gene-therapy-rare-diseases/
Find out about the experts Prof Cedric Hermans and Prof. Miguel Escobar.
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from The American Society of Gene + Cell Therapy and Pfizer.
-
Thrombotic risk is a constant threat in perioperative patients, but it has decreased with the evolution of surgical technology. Do you know how to minimise the risk of thrombosis in your surgical patients? Learn from expert colleagues from the University of Basel, Switzerland: Prof. Dimitrios Tsakiris (hematologist) and Prof. Daniel Bolliger (anesthesiologist).
In this podcast episode the two experts discuss the pathophysiology of perioperative thrombosis, how to apply perioperative thromboprophylaxis and consider special considerations such as the use of aspirin following orthopedic surgery, when to monitor anticoagulants and the use of inferior vena cava (IVC) filters as thromboprophylaxis.
This is the final episode podcast in a four-part series on thrombosis in various clinical conditions.
-
What are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic alterations?
You are listening to part 1 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs. Rohit and Rahul Gosain.
In this episode, you’ll hear GU cancer genomics expert Dr Alexander Wyatt and medical oncologist Dr Petros Grivas shine a spotlight on the pre-analytical phase challenges and biomarker testing in prostate cancer.
As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in prostate cancer and discuss best practice approaches to help minimise pre-analytical challenges.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/prostate-cancer-preanalytical-challenges-biomarker/
Or go to the video on YouTube: https://www.youtube.com/watch?v=Sxzw1SX3nao
We are pleased to share that this podcast is endorsed by the Association for Molecular Pathology (AMP) and The National Alliance of State Prostate Cancer Coalitions (NASPCC). You can find out more about AMP at https://amp.org and NASPCC at https://naspcc.org
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from AstraZeneca and Amoy Diagnostics.
This podcast is developed by cor2ed.com.
-
What are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic alterations?
You are listening to part 1 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs. Rohit and Rahul Gosain.
In this episode, you’ll hear GU cancer genomics expert Dr Alexander Wyatt and medical oncologist Dr Petros Grivas shine a spotlight on the pre-analytical phase challenges and biomarker testing in prostate cancer.
As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in prostate cancer and discuss best practice approaches to help minimise pre-analytical challenges.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/prostate-cancer-preanalytical-challenges-biomarker/
Or go to the video on YouTube: https://www.youtube.com/watch?v=Sxzw1SX3nao
We are pleased to share that this podcast is endorsed by the Association for Molecular Pathology (AMP) and The National Alliance of State Prostate Cancer Coalitions (NASPCC). You can find out more about AMP at https://amp.org and NASPCC at https://naspcc.org
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from AstraZeneca and Amoy Diagnostics.
This podcast is developed by cor2ed.com.
-
COR2ED Medical Education: Extended anticoagulation beyond the initial 3 months is indicated for all types of VTE, except in surgery-or trauma-VTE or in patients at high risk of bleeding. Are you up to date on the latest treatment options for VTE and their duration? Expert haematologists Prof. Dimitrios Tsakiris (University of Basel, Switzerland) and Prof. Jerzy Windyga (Institute of Haematology and Transfusion Medicine, Warsaw, Poland) engage in a discussion on this important topic.
This is the third podcast in a four-part series on thrombosis in various clinical conditions. In this podcast we focus on anti-thrombotic treatment for VTE and how long optimal treatment should be.
-
COR2ED Medical Education: In this podcast, Prof. Andra H. James (Professor Emeritus of Obstetrics and Gynecology, Division Maternal Fetal Medicine, Duke University Hospital, Durham, North Carolina, US) and Dr Maria Elisa Mancuso (Senior Haematology Consultant at the Center for Thrombosis and Hemorrhagic Diseases of IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy) discuss various treatment options for severe postpartum haemorrhage (also called PPH).
Experts discuss what causes PPH and how to determine the risk before and during labour with algorithms and other helpful tools. The discussion moves to when haematologic expertise is required and how collaboration can be optimized to provide the best care for patients. Furthermore, the experts share their learnings from clinical practice through discussion of specific patient cases, including patients with and without underlying bleeding disorders, as well as where haemostatic agents fit in the protocol.
-
COR2ED Medical Education: Welcome to the "Addressing Anxiety and Pain Around IUD Placement" podcast, where experts in the field, Carolyn Westhoff MD, Michal Yaron MD, and Patty Cason RN, MS, FNP-BC, delve into the world of intrauterine contraception. These seasoned clinicians share their vast experience in providing IUD placements, training others, and contributing to research trials aimed at making the process more comfortable.
IUDs are highly effective contraceptive options, but misconceptions and fears can deter patients from choosing them. In this podcast, our experts aim to dispel these concerns by discussing strategies to address anxiety and pain at every stage of IUD placement.
Join us as we explore pre-placement conversations that involve eliciting patient concerns, informed consent, and setting realistic expectations. Discover how patient engagement and tailored information play a crucial role in enhancing the overall experience.
The experts also share insights on factors that may influence pain during IUD insertion, such as cervical blocks, NSAIDs, and the importance of verbal analgesia. They shed light on the significance of patient-driven distractions and creating a calm environment to alleviate anxiety.
Tune in to uncover tips for predicting potential difficulties during insertion and the importance of adapting to each patient's unique needs. Whether discussing uterine length, history of dysmenorrhea, or a patient's past gynaecological experiences, our experts guide you through considerations that can help optimize the process.
Don't miss out on this informative and insightful podcast, where the experts provide valuable guidance to clinicians and patients alike on navigating the world of IUDs with confidence and comfort.
-
COR2ED Medical Education: In this podcast episode, Prof Dimitrios Tsakiris (Haematologist, Basel University, Switzerland) and Dr Lars Asmis (Haematologist, University of Zurich, Switzerland) discuss the association between thrombosis and cancer.
Experts discuss how different tumours affect the risk for thrombosis in patients and genetic disorders such as thrombophilia. They cover multiple scores (Khorana, Vienna, PROTECHT and Pabinger) that might help to categorise thrombosis risk in oncology patients.
The discussion moves to how cancer patients with thrombosis should be treated and the duration of treatment of low molecular weight heparins and direct oral anticoagulants (DOACs), with reference to the CLOT study and recent guidelines. In addition, they discuss whether there should be a different approach with hospital in- and out-patients
Finally, both experts discuss anticoagulation and oncocardiology and the higher incidences of atrial fibrillation reported in cancer patients.
-
COR2ED Medical Education: Dr Homa K. Ahmadzia (Maternal-Fetal Medicine specialist and Assistant Professor in the Department of Obstetrics and Gynecology at George Washington University hospital, USA) and Dr Jarmila A. Zdanowicz (Senior Consultant in Obstetrics and Gynecology, Clinical Head Maternity Unit, Fellow in Feto-Maternal Medicine, Department of Obstetrics and Gynecology, Bern University Hospital, Switzerland), discuss severe postpartum haemorrhage (also called PPH).
To set the scene, they explain important definitions and real-world incidence, in particular in higher resourced and less resourced countries. What is the difference between non-severe and severe PPH? What specialities are involved? And what are the consequences when PPH is not treated correctly? Additionally, Dr Ahmadzia and Dr Zdanowicz consider who is at risk, what measures can be used to diagnose, and the importance of prevention as well as treatment.
-
COR2ED Medical Education: Prof. Dr Amit Singal, Gastroenterologist and Hepatologist at UT Southwestern Medical Center, USA and Prof. Dr Jeroen Dekervel, GI Oncologist at UZ Leuven, Belgium, discuss the new era in treating patients with advanced HCC, focusing on treatment selection and the right time to switch to 2nd line therapy.
In this podcast, the experts give an overview of the current 1st and 2nd line systemic treatment options and sequences for patients with advanced HCC by looking into the results from different clinical trials and current guidelines. They also shine a light on the differences in approved 2nd line systemic therapies between Europe and USA.
The experts present their approach in making the decision to switch to 2nd line therapy, thereby taking toxicity, liver function and disease progression into account. They also discuss the need for comparative effectiveness data to determine the optimal 2nd line therapy.
-
COR2ED Medical Education: In this final episode, the experts discuss two patient case studies with oral SERDs (oral selective estrogen receptor degraders) and a novel therapy for ER+/HER2- advanced or metastatic breast cancer. Each patient presents unique and rare situations that shed light on the challenges confronting healthcare professionals and patients alike. They discuss the most up-to-date data and strategies for optimising treatment selection in each individual case.
This podcast is a conversation between two independent experts: Dr. Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr. Shaheenah Dawood, a consultant medical oncologist and professor of oncology at Mediclinic City Hospital, United Arab Emirates, Dubai.
-
COR2ED Medical Education: In this podcast episode, Prof Dimitrios Tsakiris (Haematologist, Basel University, Switzerland) and Assoc. Prof. Michael Nagler (Haematologist, Inselspital University Hospital, Bern, Switzerland) discuss when to monitor anticoagulation in clinical practice, covering both the technical aspects and the clinical usefulness.
The two experts discussed when monitoring of direct oral anticoagulants (DOACs) is necessary for acute situations like bleeding, surgery, and thrombolysis, while recognizing its limitations. They also discuss how to differentiate routine monitoring from critical drug level assessments, exploring the impact on clinical decisions and patient care. In addition, they discuss the benefits of anti-Xa assays for anticoagulation monitoring, including potential standardisation and shifting from traditional assays for unfractionated heparin.
This podcast is the first episode in a series of four podcasts on thrombosis in various clinical situations.
-
COR2ED Medical Education: This podcast episode provides an introduction to molecular testing in the diagnosis and treatment of cancer. Prof. David Hong from MD Anderson Cancer Center, Houston, Texas, USA and Dr Tracy Stockley from the University Health Network, Toronto, Canada discuss optimal testing strategies to identify actionable mutations.
The experts discuss genetic testing and why identifying genetic alterations is a critical step to achieving optimal patient care. They share their multidisciplinary perspectives on when to use molecular profiling and which testing methodologies should be used to identify genetic alterations to inform treatment decisions with targeted therapies throughout the patient journey.
-
COR2ED Medical Education: In this podcast, the experts deep-dive into two patient case studies of ER+/HER2- metastatic breast cancer, discussing the intricacies of treatment selection and sequencing to maximise outcomes, current data, and what to consider when adjusting dosage or switching treatments.
Dr. Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr. Shaheenah Dawood, a consultant medical oncologist and professor of oncology at Mediclinic City Hospital, United Arab Emirates, Dubai discuss oral SERDs, a novel therapy for ER+/HER2- advanced or metastatic breast cancer.
-
COR2ED Medical Education: This podcast series consists of two episodes where expert oncologists Dr Sam Klempner (Massachusetts General Hospital, USA) and Dr Lizzy Smyth (Oxford University Hospitals NHS Foundation Trust, UK) discuss patient cases focusing on gastric and gastroesophageal junction cancer.
In the second episode, Dr Klempner presents a case of a patient with advanced/metastatic gastric cancer. The two experts discuss biomarker testing such as MMR, HER2, PD-1 and CLDN 18.2. They also discuss treatment options, CPS scoring and test selection plus recent clinical trial data that are practice changing.
-
COR2ED Medical Education: This podcast series consists of two episodes where expert oncologists Dr Sam Klempner (Massachusetts General Hospital, USA) and Dr Lizzy Smyth (Oxford University Hospitals NHS Foundation Trust, UK) discuss patient cases focusing on gastric and gastroesophageal junction cancer.
In this first episode, Dr Smyth presents a case of operable localised gastric cancer. The two experts discuss the importance of MMR biomarker testing And CROSS VS FLOT management approaches. They refer to data from recent clinical trials in upper gastrointestinal cancer such as MATTERHORN, NEONIPIGA, INFINITY, KEYNOTE-811 and KEYNOTE-585 and how data might impact clinical management.
-
COR2ED Medical Education: Robert Mitchell-Thain, CEO of the PBC Foundation, Edinburgh, UK and Kath Houghton, Autoimmune Specialist Nurse, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discuss their ‘Primary Biliary Cholangitis (PBC) highlights from EASL 2023’ in this podcast.
Their discussion covers the relationship between initial symptoms and disease trajectory, the association of biochemical control and outcomes in PBC, and the impact and assessment of patient reported outcomes.
-
COR2ED Medical Education: Prof. Gideon Hirschfield, Professor of Medicine, Division of Gastroenterology, University of Toronto, Canada and Dr Emma Culver, Consultant Hepatologist and Honorary Senior Lecturer at the John Radcliffe Hospital and University of Oxford, UK discuss their ‘Primary Biliary Cholangitis (PBC) highlights from EASL 2023’ in this podcast.
Their discussion focuses on cancer risk associated with PBC; liver stiffness and prognosis; and outcomes and response prediction in second-line therapy.
- Näytä enemmän
